994 Cleland Drive
TARGET Pharmasolutions was formed in February 2015, based on the success of HCV-TARGET, a case study of the model in Hepatitis C. Formed in 2011 by Dr. Michael Fried (University of North Carolina) and Dr. David Nelson (University of Florida), there are over 10,000 patients enrolled at 58 sites worldwide. The FDA has entered into a Memo of Understanding with HCV-TARGET and is an active participant on the advisory committee directing the clinical analysis. Through the utilization of this data, one sponsor has expanded their label and others have mitigated costly Phase IV commitments.
Co-Founder, CEO and President: Meg Powell, Pharm.D.
CFO: Karen J. Adams
Co-Founder and Scientific Advisor: Michael W. Fried, MD
Co-Founder and Scientific Advisor: David Nelson, MD
Director of Clinical Operations: Laura Malahias
Director of Clinical Operations: Shelby Gainer
Director of Data Management: Ken Bergquist
Director of Medical Affairs: Monika Vainorius, MD
VP Data Management and Statistical Reporting: George DeMuth